BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 24757085)

  • 1. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors.
    Suh YG; Suh CO; Kim JS; Kim SJ; Pyun HO; Cho J
    Ann Hematol; 2012 Nov; 91(11):1785-93. PubMed ID: 22752147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X; Sun WJ; Chen SL; Zhong YP; An N; Hu Y; Zhang JJ; Liu XH
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(12):838-41. PubMed ID: 22781459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome in solitary bone plasmacytomata with combined therapy.
    Avilés A; Huerta-Guzmán J; Delgado S; Fernández A; Díaz-Maqueo JC
    Hematol Oncol; 1996 Sep; 14(3):111-7. PubMed ID: 9119355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
    Knobel D; Zouhair A; Tsang RW; Poortmans P; Belkacémi Y; Bolla M; Oner FD; Landmann C; Castelain B; Ozsahin M;
    BMC Cancer; 2006 May; 6():118. PubMed ID: 16677383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.
    Kilciksiz S; Celik OK; Pak Y; Demiral AN; Pehlivan M; Orhan O; Tokatli F; Agaoglu F; Zincircioglu B; Atasoy BM; Ozseker N; Yersal O; Niang U; Haydaroglu A;
    Am J Hematol; 2008 Sep; 83(9):702-7. PubMed ID: 18543343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Fukushima T; Nakamura T; Miki M; Sakai T; Iwao H; Nakajima A; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Anticancer Res; 2010 Sep; 30(9):3791-4. PubMed ID: 20944171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP; Chen SL
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
    Barzenje DA; Kolstad A; Ghanima W; Holte H
    Hematol Oncol; 2018 Feb; 36(1):217-223. PubMed ID: 28393375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and prognostic factors in solitary plasmacytoma.
    Finsinger P; Grammatico S; Chisini M; Piciocchi A; Foà R; Petrucci MT
    Br J Haematol; 2016 Feb; 172(4):554-60. PubMed ID: 26684545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
    Tan D; Kim K; Kim JS; Eom HS; Teoh G; Ong KH; Goh YT; Durie BG; Chng WJ; Lee JH
    Leuk Res; 2013 Sep; 37(9):1070-6. PubMed ID: 23816344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Solitary plasmacytomas of bone and extramedullary plasmacytomas].
    Yang D; Fan S; Tao H
    Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):41-4. PubMed ID: 8732111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.
    Ozsahin M; Tsang RW; Poortmans P; Belkacémi Y; Bolla M; Dinçbas FO; Landmann C; Castelain B; Buijsen J; Curschmann J; Kadish SP; Kowalczyk A; Anacak Y; Hammer J; Nguyen TD; Studer G; Cooper R; Sengöz M; Scandolaro L; Zouhair A
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):210-7. PubMed ID: 16229966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
    Sun WJ; Zhang JJ; An N; Shen M; Huang ZX; Li X
    J Int Med Res; 2016 Dec; 44(6):1462-1473. PubMed ID: 28322099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.